About
Leadership
Programs
Disease
Partnering
News
Contact Orbus
PRIVACY POLICY

Orbus Therapeutics

About
Leadership
Programs
Disease
Partnering
News
Contact Orbus
PRIVACY POLICY
Teresa Long
June 17, 2016

Orbus Therapeutics Granted Orphan Drug Designation by European Medicines Agency for Late Stage Brain Cancer

Teresa Long
June 17, 2016
Read Full Release
Newer PostOrbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
Older PostOrbus Therapeutics Secures $32.5 Million Series A Financing to Advance Late-Stage Brain Cancer Drug
Back to Top
About
Leadership
Board of Directors
Product Candidate
Programs
Disease
Partnering
News
Contact Us
Privacy Policy

Orbus Therapeutics  |  2479 E. Bayshore Road, Suite 105  |  Palo Alto, CA 94303  |  650-656-9440

Copyright © Orbus Therapeutics, Inc.  ALL RIGHTS RESERVED